Related Experiment Videos
[Regenerative medicine for pancreatic beta cells]
Hiroshi Hori1, Tadanori Nakayama, Kazutomo Inoue
1R & D (SCSKK Laboratory), Stem Cell Sciences KK and CREATE Kobe, Institute of Biomedical Research & Innovation, Kobe, Japan.
Nihon Geka Gakkai Zasshi
|September 18, 2004
Summary
Regenerative medicine advances cell therapy for diabetes mellitus (DM). Research focuses on pancreatic islet cell purification and differentiation for effective transplantation, addressing donor shortages and side effects.
Area of Science:
- Regenerative Medicine
- Cell Therapy
- Endocrinology
Context:
- Diabetes mellitus (DM) treatment faces challenges with pancreatic tissue dysfunction.
- Pancreatic and islet cell transplantation are key regenerative medicine approaches for DM.
- The Edmonton protocol advanced islet cell transplantation, but donor shortages and immunosuppression side effects persist.
Purpose:
- To review applied research in human and porcine pancreatic cell purification.
- To explore embryonic and pancreatic stem cell differentiation into insulin-producing cells.
- To discuss the development of bioartificial pancreatic transplantation systems.
Summary:
- Regenerative medicine rapidly develops therapies for organogenesis and tissue regeneration.
- Pancreatic islet cell transplantation is a regenerative approach for diabetes, facing donor limitations and side effects.
- This paper examines pancreatic cell purification, stem cell differentiation, and bioartificial pancreas development for DM treatment.
Impact:
- Advances in pancreatic cell purification and stem cell differentiation can overcome donor shortages.
- Development of immunoisolative bioartificial pancreas systems may reduce immunosuppression needs.
- Improved regenerative therapies hold promise for more effective and safer diabetes mellitus treatment.